What is Motor Pharmacology?
A novel concept of drug development.
A research group of the Hungarian Academy of Sciences at Eötvös Loránd University in Budapest.
A strong cooperation between researchers and the advisory board to exploit the scientific results.
Recently we discovered the first in vivo applicable inhibitor specific to the myosin 2 motor protein. In our body there are several different myosin 2 enzymes responsible for series of physiological functions including skeletal, smooth and cardiac muscle contraction, as well as cell division, motility and neurite outgrowth, which is related to neural plasticity and regeneration. By targeting these motor proteins with specific drugs we will be capable of alleviating symptoms of stroke or helping people suffering from spasms, scarring or fibrocyte related disorders.
30 years of myosin research: deep knowledge about the target
15 years of experience working with motor protein inhibitors and studying their mechanism of action
8 years of in silico modelling of force generation and simulation of drug binding
6 years of optimization of chemicals for research
Máté Gyimesi was awarded with the Hungarian Academy’ s QP Excellence Award. Congratulations to him
Máté is a key member of the Motorpharmacology research group. This award shows how his innovative ideas lead to a great success. We are very proud to have a colleague like him. Congratulations to him!
You can read about it here in Hungarian.
Radio interview about drug development (in Hungarian)
The Hungarian Klub Rádió interviewed Prof András Málnási Csizmadia and asked him about the long process of drug development from a molecule to the stores. You can listen to it on this link (in Hungarian).
European Muscle Conference in Kent, England
Both Motorpharmacology and Optopharma Ltd. Were present at this year’s European Muscle Conference in Kent, England. We have introduced our new compounds that will be available for sale soon. Until that visit out website for the currently available molecules www.optopharma.com.
Novel approaches targeting Brain Barriers for effective delivery of therapeutics
Máté Gyimesi and Máté Pénzes traveled to Virginia for the Targeting Brain Barriers workshop from April 29th to May 1st. This topic is essential during our research in getting the inhibitor to the right area of the damaged brain. They took a poster as well which presented our results on the Ischemic Stroke regeneration and smooth muscle myosin-2 inhibition with para-aminoblebbistatin.
16th Alpbach Motors Workshop Myosin and Muscle, and Other Motors
Anna Rauscher and András Málnási-Csizmadia participated in this year’s 16th Alpbach Motors Workshop Myosin and Muscle, and Other Motors. They both gave presentations and provided a poster for the event that contained the lab’s experimental details about myosin inhibition.
One of the posters showed our data from our research on inhibiting the skeletal muscle. The title is: A highly specific skeletal muscle relaxant decreases muscle force while heart functions remain unchanged.
The other showed data on how para-aminoblebbistatin inhibits Non-muscle and smooth muscle myosin. The title is: Ischemic stroke regeneration is accelerated by non-muscle and smooth muscle myosin-2 inhibition with para-aminoblebbistatin.
United States roundtrip
From 27th of February to the 10th of March András Málnási Csizmaida and Máté Gyimesi traveled around the U.S. giving presentations at high prestigious places.
First, they went to Baltimore for the American Biophysical Society’s Annual meeting where Ádám Horváth also joined them. They presented two of our leading projects within Motorpharmacology with posters, that were well-received.
After the success in Baltimore they traveled to the Boston University for another presentation of our results.
Strategic partnership with NeuroCT Ltd, Pécs
NeuroCT’s partnership in the project is a milestone in the preclinical phase of our drug development. Founded 25 years ago, NeuroCT is one of the most acknowledged clinical neuroscience centers in the Eastern European region, that has gained considerable experience in the treatment of stroke, while its Clinical Neuroscience Research Group has internationally gained R&D and innovation experience.
December the 16th, 2018
A hungarian compound might help people suffering from ischemic stroke ( M1, Ma reggel)
András Málnási Csizmadia as well as Máté Gyimesi have talked about our research for the audience of a hungarian TV channel. You can watch it here ( 07:38-15:46)
December the 5th, 2018
ELTE’s Innovative Researcher Award for Motor Pharmacology’s patent
In recognition of the outstanding research achievement, ELTE established the ELTE Innovative Researcher Award in 2009. It is our pleasure that this year our research group has won this award for our stroke project.
October the 19th, 2018
Meeting with BBCA and cooperation with University of Bengbu
In October we have met the management of BBCA and signed the Memorandum of Cooperation with Bengbu University, China.
It was our honour to meet the management of BBCA, the third largest vitamin C producer in the World. Vitamin C was firstly isolated by Albert Szent-Györgyi, who also discovered myosin and founded the ancestor of the Department of Biochemistry at Eötvös Loránd University.
September the 14th-16th , 2018
Europhysiology, 2018 QEII Centre LONDON, UK
Plenary lecture was given by Prof. András Málnási Csizmadia regarding Motor Pharmacology: Novel inhibitors for different myosin-2 isoforms
September the 10th, 2018
You can meet us at the Capital of Sciences, Budapest, 23rd of September
We are confident that inspiring younger generation is very important so that we will join this great event, www.tudomanyokfovarosa.hu on the 23rd of September, 2018
September the 3rd, 2018
European Muscle Conference, Budapest
This meeting was the annual gathering of the members of the European Society for Muscle Research. Dr. Máté Gyimesi’s lecture was about: Development of a highly specific skeletal muscle relaxant directly acting on the myosin motor domain
July the 26th, 2018
Our new revies entitled “Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential” has been published in Trends in Biochemical Sciences.
We constructed a SAR analysis based on blebbistatin derivatives and discuss the pharmacological perspectives of blebbistatin development. We also synthetize literature data on its characteristics and compare potentially useful alternatives, like para-nitroblebbistatin or para-aminoblebbistatin. The preprint is available here.
May the 25th, 2018
Our new research article has been published in Scientific Reports
Our new paper entitled “Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog” has been published in Scientific Reports. You can have a look at the article here.
May the 16th to 18th, 2018
You can meet us at the Stroke Conference, Göthenburg, Sweden
András-Málnási Csizmadia, Máté Gyimesi as well as Máté Pénzes are participating the 4th European Stroke Conference in Göthenburg.